Fund Overview
13F Filed: 2026-02-13As of 2025 Q4, Atlas Venture Life Science Advisors, Llc manages $865M in reported 13F assets , holds 9 positions with +100.00% top-10 concentration , and delivered a 1-year return of +43.60% on its disclosed equity portfolio. Filing 13F reports since 2022.
Key Personnel
Activity Summary — 2025 Q4
Top Buys
| Stock | % Impact |
|---|---|
| KYMR Kymera Therapeu.. | +9.88% |
| DYN Dyne Therapeuti.. | +7.29% |
| SION Sionna Therapeu.. | +1.95% |
| DAWN Day One Biophar.. | +1.67% |
| N/A Generation Bio,.. | +0.54% |
| QTTB Q32 Bio, Inc... | +0.32% |
Top Sells
| Stock | % Impact |
|---|---|
| KRRO Korro Bio, Inc... | -5.24% |
| IRON Disc Medicine, .. | -2.47% |
| GBIO Generation Bio,.. Sold All 😨 Was: 0.67% | -0.59% |
| IMA ImageneBio, Inc.. Sold All 😨 Was: 0.41% | -0.36% |
Activity Summary
Sector Allocation Trends
Holdings Analysis
Positions Dynamics
Portfolio Analytics — Latest
Atlas Venture Life Science Advisors, LLC risk dashboard covering volatility, beta, value-at-risk, drawdowns, concentration, factor tilts, benchmark comparison, and stress testing for the latest disclosed portfolio.
Tracking institutional benchmark deviation
Best Strategy vs. Benchmarks
Strategy Backtester: Atlas Venture Life Science Advisors, LLC
Replicate top holdings performance • Compare vs benchmarks • Optimize N
Find the best N! Test multiple portfolio sizes at once to discover the optimal configuration.
Risk insights! Identify periods when the fund lagged the benchmark – critical for timing entries.
⏱ Run Backtest
Liquid Glass Edition
👆 Click the button to launch tickers!
Backtesting Atlas Venture Life Science Advisors, LLC's top 10 holdings against SPY identified 7 underperformance periods. Worst drawdown: 2024-09 – 2025-03 (-65.1% vs SPY, 7 quarters).
The ticker-level breakdown shows how each of Atlas Venture Life Science Advisors, LLC's top holdings contributed to portfolio returns quarter by quarter. Strongest recent contributors inside the last 5 years of the quarterly Top 10 backtest window: KYMR (2022 Q1 – 2025 Q3, +73.7 pts), IRON (2022 Q4 – 2025 Q3, +24.6 pts), DYN (2022 Q1 – 2025 Q3, +24.5 pts), SION (2025 Q1 – 2025 Q3, +14.9 pts), DAWN (2022 Q1 – 2025 Q3, +14.9 pts) .
Frequently Asked Questions
What does Atlas Venture Life Science Advisors, Llc invest in?
What is Atlas Venture Life Science Advisors, Llc's AUM?
How concentrated is Atlas Venture Life Science Advisors, Llc's portfolio?
How to track Atlas Venture Life Science Advisors, Llc 13F filings?
Who manages Atlas Venture Life Science Advisors, Llc?
Disclaimer: 13Foresight is not a registered investment adviser, broker-dealer, or financial planner. All information on this site is provided solely for informational and educational purposes and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. Portfolio backtests shown on this page are hypothetical and simulated — they do not represent actual trading results and were constructed with the benefit of hindsight. Actual results would differ materially. 13F filings disclose only long equity positions valued above $10,000, submitted up to 45 days after quarter-end; they do not capture short positions, options, bonds, cash, private investments, or non-U.S. securities. A fund's backtest performance may not reflect its actual returns, as managers frequently generate alpha through strategies not visible in 13F data. Past performance is not indicative of future results. All data sourced from public SEC EDGAR filings. Use at your own risk. Full Terms of Use.